FDA Revisits Old Issues For Novartis' COPD Drug Indacaterol At Panel Review
This article was originally published in The Pink Sheet Daily
The Pulmonary-Allergy Drugs Advisory Committee is being asked whether safety and efficacy have been established for two doses of the chronic obstructive pulmonary disease treatment Arcapta, the same problem that caused an earlier "complete response" letter.
You may also be interested in...
FDA's Pulmonary-Allergy Drugs Advisory Committee endorses approval of the 75 mcg dose of indacaterol but recommends against approval of Novartis' preferred 150 mcg dose of the chronic obstructive pulmonary disease drug.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.